PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
15.44%
Net income growth at 50-75% of CRWD's 30.05%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
-6.61%
Negative yoy D&A while CRWD is 6.21%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-96.52%
Negative yoy deferred tax while CRWD stands at 61.99%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
3.05%
Less SBC growth vs. CRWD's 13.23%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
129.00%
Slight usage while CRWD is negative at -200.00%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
-177.16%
Both yoy AR lines negative, with CRWD at -124.34%. Martin Whitman would suspect an overall sector lean approach or softer demand.
196.85%
Inventory growth of 196.85% while CRWD is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
139.82%
AP growth well above CRWD's 184.01%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
1368.75%
Growth well above CRWD's 100.00%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-406.38%
Negative yoy while CRWD is 14.15%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-30.98%
Both yoy CFO lines are negative, with CRWD at -13.35%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-14.22%
Negative yoy CapEx while CRWD is 64.44%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-885.94%
Negative yoy acquisition while CRWD stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
11.08%
Less growth in investment purchases vs. CRWD's 31.64%, preserving near-term liquidity. David Dodd would confirm no strategic investment opportunities are lost.
34.12%
We have some liquidation growth while CRWD is negative at -36.63%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
-342.42%
Both yoy lines negative, with CRWD at -9.26%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-140.52%
We reduce yoy invests while CRWD stands at 52.10%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
96.43%
We slightly raise equity while CRWD is negative at -200.00%. John Neff sees competitor possibly preserving share count or buying back shares.
46.12%
Buyback growth of 46.12% while CRWD is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.